• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited

    11/12/25 4:30:09 PM ET
    $HKPD
    Other Pharmaceuticals
    Health Care
    Get the next $HKPD alert in real time by email
    6-K 1 ea0265263-6k_hongkong.htm REPORT OF FOREIGN PRIVATE ISSUER
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16

    OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of November 2025

     

    Commission File Number 001-42468

     

    Hong Kong Pharma Digital Technology Holdings Limited

    (Registrant’s Name)

     

    Room B1, 5/F., Well Town Industrial Building,
    13 Ko Fai Road, Yau Tong, Kowloon

    Hong Kong

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒      Form 40-F ☐

     

     

     

     

     

    INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

     

    Resignation of Independent Directors

     

    On November 6, 2025, the Board of Directors (the “Board”) of Hong Kong Pharma Digital Technology Holdings Limited (the “Company”) received and accepted the resignation of Ms. Raina Zou (“Ms. Zou”) from her position as Independent Director, chairperson of the audit committee of the Board, member of the compensation committee of the Board and member of the nominating and corporate governance committee of the Board. On the same date, the Board also received and accepted the resignation of Dr. King Yin Lai (“Mr. Lai”) from his position as Independent Director, member of the audit committee of the Board, chairperson of the compensation committee of the Board and member of the nominating and corporate governance committee of the Board. Both Ms. Zou and Mr. Lai resigned for personal reasons and not due to any disagreement with the Company or the Board on any matter relating to the Company’s operations, policies, or practices.

     

    Appointment of Independent Director

     

    To fill the vacancy created by Ms. Zou’s resignation until the Company’s next annual general meeting called for the election of directors, the Board appointed Ms. Jingyan Wu (“Ms. Wu”) to serve as an independent director, chairperson of the audit committee of the Board, member of the compensation committee of the Board and member of the nominating and corporate governance committee of the Board, effective on November 6, 2025.

     

    Jingyan Wu, aged 55, has over 20 years of professional experience in accounting and auditing, including over 10 years serving at U.S. public companies and public accounting firms. Ms. Wu previously served as chief financial officer of EZGO Technologies Ltd. (Nasdaq: EZGO) and chief financial officer of Jiangsu EZGO Electronic Technologies, Co., Ltd., from September 2020 to August 2025. From June 2018 to August 2020, Ms. Wu served as a Senior Internal Auditor of MSIG Holdings (U.S.A.) Inc., a member of MS&AD Insurance Group Holdings Inc., one of the world’s top property and casualty insurance providers located in Japan. From November 2009 to June 2018, Ms. Wu served as a Senior Internal Auditor of Children’s Place Inc. (Nasdaq: PLCE), an American specialty retailer of children’s apparel and accessories. From February 2007 to November 2009, she served as a Senior Auditor of Deloitte Touche Tohmatsu Limited. Ms. Wu has been a Certified Public Accountant since 2005, and is a licensed Certified Public Accountant in the States of New Jersey and Illinois. Ms. Wu received her Bachelor’s degree from Shanghai University of Finance and Economics in June 1993 and Master’s degree in Accountancy from University of Illinois, Urbana-Champaign in May 2004.

     

    There are no arrangements or understandings between Ms. Wu and any other persons pursuant to which he was selected as a director, and there are no related party transactions involving Ms. Wu that are reportable under Item 7.B of Form 20-F. There are and have been no transactions in which Ms. Wu has an interest requiring disclosure under Item 404(a) of Regulation S-K. The Board has determined that Ms. Wu is an “independent director” as defined under Nasdaq Listing Rule 5605(a)(2).

     

    The Company agrees to pay Ms. Wu an annual compensation of US$25,000, payable in arrears, in equal installments quarterly. Under an indemnification agreement between the Company and Ms. Wu in the Company’s standard form for officers or directors of the Company, the Company will indemnify Ms. Wu if Ms. Wu is a party to or threatened to be made a party in any proceedings in connection with Ms. Wu’s service as a director of the Company.

     

    To fill the vacancy created by Mr. Lai’s resignation until the Company’s next annual general meeting called for the election of directors, the Board also appointed Mr. Yao Mike Zhou, an independent director of the Company and member the nominating and corporate governance committee of the Board (“Mr. Zhou”), to serve as member of the audit committee of the Board and chairperson of the compensation committee of the Board, effective on November 6, 2025.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Date: November 12, 2025

     

      Hong Kong Pharma Digital Technology Holdings Limited
       
      /s/ Liang Chenyu
      Name:  Liang Chenyu
      Title: Director and Chief Executive Officer

     

    2

     

     

     

    Get the next $HKPD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HKPD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HKPD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency

    HONG KONG, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD) (the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received a notification letter (the "Notification Letter") dated January 12, 2026 from Nasdaq's Listing Qualifications Department indicating that the closing bid price of the Company's class A ordinary shares of par value of US$0.001 each was below the minimum requirement of US$1.00 per share for 30 consecutive business days from November 26, 2025 through January 9, 2026, and the Company was therefore currently not in compliance with the min

    1/16/26 4:30:00 PM ET
    $HKPD
    Other Pharmaceuticals
    Health Care

    Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders

    HONG KONG, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that all proposals at the Company's 2025 annual meeting of stockholders held on December 12, 2025 local time were duly passed. The shareholders of the Company passed and approved the following proposals: Proposal No. 1: The re-election of five directors, Chenyu Liang, Lap Sun Wong, Mike Yao Zhou, Jingyan Wu, Dr. Kam Leung Chan, each to serve until the 2026 Annual Meeting of Stockholders; Proposal No. 2: The ratific

    12/17/25 4:30:00 PM ET
    $HKPD
    Other Pharmaceuticals
    Health Care

    Hong Kong Pharma Digital Technology Holdings Limited Reports Financial Results for the Six Months Ended September 30, 2024

    HONG KONG, March 28, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced its unaudited financial results for the six months ended September 30, 2024. Financial Highlights for the Six Months Ended September 30, 2024: Net Revenues: The Company reported net revenues of $11,091,189, an increase of 58.9% compared to $7,009,209 for the same period in 2023.Revenue Breakdown:Six Months endedSeptember 30,2024 Six Months endedSeptember 30,2023 Supply chain services $ 6,329,678 $ 4,646,951 Procurement an

    3/28/25 4:50:00 AM ET
    $HKPD
    Other Pharmaceuticals
    Health Care

    $HKPD
    SEC Filings

    View All

    SEC Form EFFECT filed by Cellyan Biotechnology Co. Ltd

    EFFECT - Cellyan Biotechnology Co., Ltd (0002007702) (Filer)

    4/9/26 12:15:14 AM ET
    $HKPD
    Other Pharmaceuticals
    Health Care

    SEC Form F-1 filed by Cellyan Biotechnology Co. Ltd

    F-1 - Cellyan Biotechnology Co., Ltd (0002007702) (Filer)

    3/27/26 3:19:24 PM ET
    $HKPD
    Other Pharmaceuticals
    Health Care

    SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd

    6-K - Cellyan Biotechnology Co., Ltd (0002007702) (Filer)

    3/26/26 7:48:08 PM ET
    $HKPD
    Other Pharmaceuticals
    Health Care

    $HKPD
    Leadership Updates

    Live Leadership Updates

    View All

    Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders

    HONG KONG, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that all proposals at the Company's 2025 annual meeting of stockholders held on December 12, 2025 local time were duly passed. The shareholders of the Company passed and approved the following proposals: Proposal No. 1: The re-election of five directors, Chenyu Liang, Lap Sun Wong, Mike Yao Zhou, Jingyan Wu, Dr. Kam Leung Chan, each to serve until the 2026 Annual Meeting of Stockholders; Proposal No. 2: The ratific

    12/17/25 4:30:00 PM ET
    $HKPD
    Other Pharmaceuticals
    Health Care

    $HKPD
    Financials

    Live finance-specific insights

    View All

    Hong Kong Pharma Digital Technology Holdings Limited Reports Financial Results for the Six Months Ended September 30, 2024

    HONG KONG, March 28, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) ("HKPD" or the "Company"), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced its unaudited financial results for the six months ended September 30, 2024. Financial Highlights for the Six Months Ended September 30, 2024: Net Revenues: The Company reported net revenues of $11,091,189, an increase of 58.9% compared to $7,009,209 for the same period in 2023.Revenue Breakdown:Six Months endedSeptember 30,2024 Six Months endedSeptember 30,2023 Supply chain services $ 6,329,678 $ 4,646,951 Procurement an

    3/28/25 4:50:00 AM ET
    $HKPD
    Other Pharmaceuticals
    Health Care